Navigation Links
Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care
Date:11/1/2011

FARMINGDALE, N.Y., Nov. 1, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical and medical applications, announced its recent attendance at the 26th Annual Clinical Symposium on Advances in Skin and Wound Care held in National Harbor, MD during September, 2011.  Misonix exhibited and demonstrated its SonicOne® Ultrasonic Wound Cleansing and Debridement System to many of the more than 1,000 clinicians in attendance.

In addition, a clinical poster was presented that focused on the use of Contact Low Frequency Ultrasound as a Treatment Approach for Recalcitrant Wounds and Skin Conditions.  John Bowman, PT, CWS, and Martin Smith, Technician, both from Retreat Doctors' Hospital, Richmond, VA, and Dana Wassum, DPT, from Virginia Commonwealth University, Richmond, VA, co-authored and presented their findings.  The poster session focused on two separate clinical cases where wound closure had not been accomplished using standard wound care practices and compression.  However, when contact, low frequency ultrasound, delivered by the SonicOne, was added to the treatment regimen, progression through the normal phases of wound healing began, with complete closure probable within a reasonable period of time.  One conclusion of the authors was that the use of contact low frequency ultrasound as an adjunctive treatment modality appeared to be a very effective strategy to remove devitalized tissue in regard to efficacy, ease of use and outcome measures.

The SonicOne is an innovative wound care system designed to help address the challenges chronic wounds present to the patient, the healthcare professional and the healthcare system.  The SonicOne System establishes a new standard in wound bed preparation, an essential first step in the wound healing process.

"Misonix is pleased to demonstrate its commitment to the rapidly expanding wound care market by supporting important educational programs like the Clinical Symposium on Advances in Skin and Wound Care," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We believe our wound care platform makes an important contribution to improving patient outcomes and we are pleased when data is presented that validates our investment in wound care research and development."

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques
2. Misonix Announces New Distribution Agreement for Austria, Germany & Switzerland
3. Misonix Announces the Sale of Its Laboratory and Forensic Safety Products Business for $1.5 Million
4. Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results
5. Misonix Schedules Fourth Quarter and Year-End Fiscal 2011 Financial Results Conference Call; September 20, 2011 at 4:30 p.m. Eastern
6. Misonix Announces New Distribution Agreement for Australia and New Zealand
7. Misonix Announces Entry Into Surgical Wound Debridement
8. Misonix Announces Update of Product Registration in Brazil
9. Misonix Announces New Distribution Agreement for Taiwan
10. Misonix Announces New Distribution Agreement for Chile
11. Misonix Announces Settlement of PuriCore Litigation, Including Entry into a U.S. Distribution Agreement for PuriCores Advanced Wound Care Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Frontier Pharma: ... Commercializing First-in-Class Innovation Chronic Obstructive ... with chronic inflammation of the airways and lungs. ... symptoms make the disease one of the leading ... death in the world. COPD is linked to ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
(Date:2/4/2016)... , Feb. 4, 2016  Blueprint Medicines ... discovering and developing highly selective investigational kinase medicines ... the appointment to its board of directors of ... with nearly 30 years of industry-related experience. ... of Blueprint Medicines. "Lonnel,s strong strategic experience developing ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s ... the tips of your toes. Foot massage, whether administered by a professional masseuse or ... relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has taken ...
(Date:2/5/2016)... Rafael, CA (PRWEB) , ... February 05, 2016 , ... ... with ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ChildLight ... New Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder Lisa ...
(Date:2/5/2016)... ... 05, 2016 , ... Give To Cure today announced that it ... to Give To Cure’s campaign that is crowdfunding clinical trials to help find cures ... payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... In sleep, ... form as a dream. A hallmark feature of patients with eating disorders is significant ... The eating disorder behaviors and obsessions are regarded as maladaptive means for coping with ...
Breaking Medicine News(10 mins):